Complete pathological response following down-staging chemoradiation in locally advanced pancreatic cancer: Challenging the boundaries

AZ Khan, V Pitsinis, SS Mudan

AZ Khan, V Pitsinis, SS Mudan, Department of Gastrointestinal Surgery, Royal Marsden Hospital, Fulham Road, London, United Kingdom
Correspondence to: Aamir Z Khan, FRCS Eng (Gen), Department of Gastrointestinal Surgery, Royal Marsden Hospital, Chelsea, London SW3 6JJ, United Kingdom. aamirzkhan@yahoo.co.uk
Telephone: +44-207-3528171 Fax: +44-207-8082988
Received: September 22, 2006 Revised: September 29, 2007

Abstract

Pancreatic cancer is an aggressive malignancy, relatively resistant to chemotherapy and radiotherapy, which usually presents late. Disease specific mortality approaches unity despite advances in adjuvant therapy. We present the first reported case of complete pathological response following neoadjuvant therapy in a locally advanced pancreatic adenocarcinoma.

INTRODUCTION

Pancreatic cancer is an aggressive intra-abdominal malignancy and approximately 3000 new cases are diagnosed each year in the United Kingdom, most of them usually present with advanced pancreatic cancer and only 10%-20% of patients are resectable at presentation. Surgery with complete resection of the primary lesion offers the only chance of long term survivorship and cure in this cohort of patients. For locally advanced pancreatic cancer, several chemotherapeutic and combined modality regimens have been described, generally with conflicting results, poor response rates, high toxicity, not changing the natural history of the disease. Several novel and new regimens are being tried in the neoadjuvant setting in patients with locally advanced pancreatic cancer at presentation in the hope of down-staging the disease and rendering it resectable. We present the first case of complete pathological response following down-staging chemotherapy.
DISCUSSION

Pancreatic cancer remains a formidable challenge to clinicians and carries a tumour specific mortality of nearly 100%\[^1\]. Complete resection offers the only hope of cure but is applicable to the minority of patients that present with resectable disease. Approximately 10%-20% of patients present with locally advanced pancreatic cancer without evidence of distant metastatic spread at the time of diagnosis. Prior to the use of neoadjuvant therapy these patients were denied surgery with curative intent and had very short survival times after diagnosis.

Several neoadjuvant regimens have been described to try and downstage locally advanced pancreatic cancer and chemoradiation here is considered as an induction therapy to reduce tumour volume, lymph node disease and extent of vascular involvement\[^2-5\]. In locally advanced pancreatic cancer, complete remissions have not yet been described\[^6\]. Neoadjuvant therapy has its own intrinsic advantages in that it theoretically increases vulnerability of cancer cells because of intact vasculature, better tumour cell oxygenation and probability of sterilizing cells at the resection margin. It also affords a test of the biology of the disease in that patients with progressive disease on chemotherapy can be spared an exploratory laparotomy and trial dissection and managed along the palliative pathway. The risk of pancreatic fistula also seems to be decreased in previously irradiated field\[^7\].

Several regimens have been described and utilized in the neoadjuvant setting for locally advanced pancreatic cancer in an attempt to induce regression of the disease and render it resectable with conflicting results\[^8\]. 5-FU based regimens were originally described but had poor response rates and eventually gave way to gemcitabine based regimens\[^9\]. Combined modality treatments using gemcitabine in combination with other agents like capecitabine, oxalipatin, bevacizumab and irinotecan have shown promise with prolonged progression-free intervals and better response rates\[^10-12\]. In these settings gemcitabine is used as a radiation sensitizer and combination with external beam radiotherapy remains a popular regimen\[^13\].

Complete pathological response remains an elusive goal in this subset of patients who may then be offered a pancreatoduodenectomy with the aim of long term survivorship or cure, who if untreated have a very short life expectancy. The future of combined modality therapy for locally advanced pancreatic cancer will focus on the development of newer biological agents that target specific alterations in the cancer cells including vascular endothelial growth factor, epidermal growth factor and matrix metalloproteases\[^14,15]\.

In conclusion, complete pathological response following down-staging chemotherapy is possible in patients with locally advanced pancreatic cancer and may offer the patient a chance at long term survival or cure.

REFERENCES

1. Kim HJ, Czischke K, Brennan MF, Conlon KC. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg 2002; 6: 763-769
2. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins RA, Sauter PK, Coleman J, Hruban RH, Lillmee KD. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579
3. Cleary SP, Cryle R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004; 198: 722-731
4. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewah DS. Radiosensitization of pancreatic cancer cells by 2,2-difluoro-2-deoxycurtidine. Int J Radiat Oncol Biol Phys 1996; 34: 867-872
5. Willett CG, Lewandrowski K, Warshaw AL, Eifrid J, Compton CC. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993; 217: 144-148
6. Mancuso A, Calabrò F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 2006; 58: 231-241
7. Hoffman JP, Cooper HS, Young NA, Pendurthi TK. Preoperative chemotherapy of chemoradiotherapy for the treatment of adenocarcinoma of the pancreas and ampulla of Vater. J Hepatobiliary Pancreat Surg 1998; 5: 251-254
8. Wanebo HJ, Glickman AS, Vezeridis MP, Clark J, Tibbetts L, Konei RJ, Levy A. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg 2000; 135: 81-87; discussion 88
9. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Dureux M, Aiuti E, Taieb J, Faroux R, Lepere C, de Gramont A. Gemcitabine in combination

Figure 1 Initial CT scan showing the inoperable mass in the pancreatic head.

Figure 2 CT scan after completion of chemotherapy showing the operable disease.
with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. *J Clin Oncol* 2005; **23**: 3509-3516

11 Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi C, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. *Lancet Oncol* 2005; **6**: 369-376

12 Yip D, Goldstein D. Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer. *Cancer Treat Rev* 2005; **31**: 236-241

13 Mornex F, Girard N, Delpero JR, Partensky C. Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment. *Semin Radiat Oncol* 2005; **15**: 226-234

14 Dickler A, Abrams RA. Radiochemotherapy in the management of pancreatic cancer--part II: use in adjuvant and locally unresectable settings. *Semin Radiat Oncol* 2005; **15**: 235-244

15 Heidelberger C, Griesbach L, Montag BJ, Mooren D, Cruz O, Schnitzer RJ, Grunberg E. Studies on fluorinated pyrimidines. II. Effects on transplanted tumors. *Cancer Res* 1958; **18**: 305-317